(Q47304637)

English

Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer

scientific article published in April 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17243161

Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17243161

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Erb-b2 receptor tyrosine kinase 2

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Larry E Morrison

1

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17243161

Susan S Jewell

2

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17243161

Lydia Usha

3

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17243161

Beth A Blondin

4

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17243161

Ruta D Rao

5

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17243161

Bita Tabesh

6

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17243161

Matthew Kemper

7

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17243161

Marta Batus

8

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17243161

John S Coon

9

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17243161

publication date

1 April 2007

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17243161

Genes, Chromosomes and Cancer

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17243161

46

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17243161

4

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17243161

397-405

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17243161

COX-2 inhibits anoikis by activation of the PI-3K/Akt pathway in human bladder cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FGCC.20419

21 January 2018

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FGCC.20419

21 January 2018

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1002%2FGCC.20419

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene copy mapping of the ERBB2/TOP2A region in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FGCC.20419

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FGCC.20419

7 January 2021

based on heuristic

inferred from DOI database lookup

Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1002%2FGCC.20419

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis

1 reference

https://api.crossref.org/works/10.1002%2FGCC.20419

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FGCC.20419

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

1 reference

https://api.crossref.org/works/10.1002%2FGCC.20419

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1002%2FGCC.20419

7 January 2021

based on heuristic

inferred from DOI database lookup

HER-2/neu as a predictive marker of response to breast cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FGCC.20419

7 January 2021

based on heuristic

inferred from DOI database lookup

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

1 reference

https://api.crossref.org/works/10.1002%2FGCC.20419

7 January 2021

based on heuristic

inferred from DOI database lookup

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1002%2FGCC.20419

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FGCC.20419

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3.

1 reference

https://api.crossref.org/works/10.1002%2FGCC.20419

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulation of cyclooxygenase-2 pathway by HER2 receptor

1 reference

https://api.crossref.org/works/10.1002%2FGCC.20419

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1002%2FGCC.20419

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/GCC.20419

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17243161

release_ph27p4zrvrecbb4qpvifv343de

1 reference

https://api.fatcat.wiki/v0/release/ph27p4zrvrecbb4qpvifv343de

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17243161

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47304637&oldid=2151373684"